A detailed history of Nuveen Asset Management, LLC transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 243,098 shares of EWTX stock, worth $6.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
243,098
Previous 338,004 28.08%
Holding current value
$6.49 Million
Previous $6.17 Million 28.99%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$15.08 - $21.23 $1.43 Million - $2.01 Million
-94,906 Reduced 28.08%
243,098 $4.38 Million
Q1 2024

May 13, 2024

BUY
$9.25 - $19.97 $1.71 Million - $3.69 Million
184,712 Added 120.5%
338,004 $6.17 Million
Q4 2023

Feb 14, 2024

BUY
$5.51 - $12.1 $4,441 - $9,752
806 Added 0.53%
153,292 $1.68 Million
Q3 2023

Nov 14, 2023

SELL
$5.73 - $7.69 $5,821 - $7,813
-1,016 Reduced 0.66%
152,486 $873,000
Q2 2023

Aug 14, 2023

BUY
$5.71 - $10.29 $317,921 - $572,926
55,678 Added 56.92%
153,502 $1.19 Million
Q1 2023

May 15, 2023

SELL
$6.66 - $11.33 $59,127 - $100,587
-8,878 Reduced 8.32%
97,824 $652,000
Q4 2022

Feb 14, 2023

SELL
$7.58 - $11.08 $37,195 - $54,369
-4,907 Reduced 4.4%
106,702 $954,000
Q3 2022

Nov 14, 2022

SELL
$8.08 - $13.58 $22,042 - $37,046
-2,728 Reduced 2.39%
111,609 $1.1 Million
Q2 2022

Aug 15, 2022

BUY
$5.67 - $9.87 $23,938 - $41,671
4,222 Added 3.83%
114,337 $910,000
Q1 2022

May 16, 2022

BUY
$9.1 - $18.97 $152,561 - $318,032
16,765 Added 17.96%
110,115 $1.15 Million
Q4 2021

Feb 14, 2022

BUY
$14.41 - $22.41 $927,816 - $1.44 Million
64,387 Added 222.31%
93,350 $1.8 Million
Q3 2021

Nov 12, 2021

SELL
$14.11 - $24.1 $252,244 - $430,835
-17,877 Reduced 38.17%
28,963 $501,000
Q2 2021

Aug 16, 2021

BUY
$21.33 - $30.25 $999,097 - $1.42 Million
46,840 New
46,840 $999,000

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $1.69B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.